Nantahala Capital Management LLC Has $8.25 Million Stock Holdings in Unicycive Therapeutics, Inc. (NASDAQ:UNCY)

Nantahala Capital Management LLC raised its position in shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) by 268.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,391,994 shares of the company's stock after acquiring an additional 7,571,636 shares during the period. Nantahala Capital Management LLC owned approximately 10.01% of Unicycive Therapeutics worth $8,253,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in UNCY. Virtu Financial LLC increased its holdings in shares of Unicycive Therapeutics by 566.8% during the 3rd quarter. Virtu Financial LLC now owns 73,975 shares of the company's stock worth $30,000 after purchasing an additional 62,881 shares during the period. Northern Trust Corp increased its stake in Unicycive Therapeutics by 142.4% during the fourth quarter. Northern Trust Corp now owns 58,181 shares of the company's stock valued at $46,000 after acquiring an additional 34,183 shares during the period. XTX Topco Ltd raised its holdings in Unicycive Therapeutics by 142.2% in the 4th quarter. XTX Topco Ltd now owns 171,463 shares of the company's stock valued at $136,000 after acquiring an additional 100,679 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Unicycive Therapeutics by 30.3% in the 4th quarter. Geode Capital Management LLC now owns 524,487 shares of the company's stock worth $417,000 after acquiring an additional 122,089 shares during the period. Finally, Vivo Capital LLC grew its holdings in shares of Unicycive Therapeutics by 123.0% during the 4th quarter. Vivo Capital LLC now owns 9,970,152 shares of the company's stock worth $7,918,000 after purchasing an additional 5,500,000 shares in the last quarter. 40.42% of the stock is currently owned by institutional investors.

Unicycive Therapeutics Trading Up 0.3 %

UNCY stock traded up $0.00 during trading on Friday, hitting $0.65. 484,613 shares of the stock traded hands, compared to its average volume of 1,446,246. The stock has a market cap of $78.06 million, a price-to-earnings ratio of -0.67 and a beta of 2.15. The company has a 50 day simple moving average of $0.58 and a 200 day simple moving average of $0.60. Unicycive Therapeutics, Inc. has a one year low of $0.20 and a one year high of $1.21.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.13). As a group, analysts predict that Unicycive Therapeutics, Inc. will post -0.23 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on UNCY shares. Guggenheim assumed coverage on shares of Unicycive Therapeutics in a research note on Monday, April 21st. They set a "buy" rating and a $6.00 price target on the stock. HC Wainwright restated a "buy" rating and set a $7.50 price target on shares of Unicycive Therapeutics in a research note on Friday, April 11th.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.